Halozyme Therapeutics Inc. (NASDAQ:HALO) had its target price increased by Piper Jaffray Cos. from $15.00 to $18.00 in a research note released on Friday morning. They currently have an overweight rating on the biopharmaceutical company’s stock.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Several other equities analysts have also recently weighed in on HALO. Canaccord Genuity reissued a buy rating and set a $11.00 price target on shares of Halozyme Therapeutics in a report on Monday, June 6th. Wells Fargo & Co. reissued a buy rating on shares of Halozyme Therapeutics in a report on Wednesday, June 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $16.11.

Shares of Halozyme Therapeutics (NASDAQ:HALO) opened at 12.43 on Friday. The firm’s 50-day moving average price is $10.44 and its 200 day moving average price is $9.78. Halozyme Therapeutics has a 52 week low of $6.96 and a 52 week high of $18.65. The company’s market cap is $1.59 billion.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.06. The firm had revenue of $33.30 million for the quarter, compared to analysts’ expectations of $29.94 million. Halozyme Therapeutics had a negative return on equity of 234.15% and a negative net margin of 44.90%. The company’s revenue was down 23.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.02 EPS. On average, equities research analysts forecast that Halozyme Therapeutics will post ($0.91) EPS for the current year.

A number of institutional investors have recently made changes to their positions in HALO. Amalgamated Bank boosted its position in shares of Halozyme Therapeutics by 3.0% in the second quarter. Amalgamated Bank now owns 11,518 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 338 shares in the last quarter. Analytic Investors LLC raised its stake in shares of Halozyme Therapeutics by 0.5% in the second quarter. Analytic Investors LLC now owns 75,651 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 353 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Halozyme Therapeutics by 2.6% in the second quarter. Principal Financial Group Inc. now owns 19,188 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 492 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Halozyme Therapeutics by 13.5% in the second quarter. Royal Bank of Canada now owns 14,200 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 1,685 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its stake in shares of Halozyme Therapeutics by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 15,269 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 1,842 shares during the last quarter. 80.41% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.

5 Day Chart for NASDAQ:HALO

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.